Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a U.S.-based early-stage biotechnology company developing next-generation brain-penetrant allosteric small molecules through its Magellan™ computational platform. Its lead clinical candidate, GT-02287, is being advanced for Parkinson’s disease and other neurodegenerative disorders, while the company also pursues discovery, preclinical work, and partnering opportunities around its platform technology.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead therapeutic program being advanced through clinical development for neurodegenerative disease.
Earlier-stage small-molecule programs generated from the company’s discovery efforts.
Magellan™ identifies novel allosteric binding sites and potential drug candidates.
Collaborations and licensing arrangements that monetize platform technology and know-how.
Customers
The company’s direct counterparties are pharmaceutical and biotechnology partners that may license or co-develop programs built on the Magellan™ platform. Its eventual end customers, if products are approved, would be patients and healthcare providers in neurology and other high-unmet-need therapeutic areas. At this stage, the business is funded primarily through capital markets and potential collaboration income rather than product sales.
Buy access to platform-enabled discovery, licensing, or co-development rights to accelerate pipeline creation.
Regulators, investigators, and trial sites that support advancement of GT-02287 and future candidates.
Would use approved therapies for Parkinson’s disease and other neurodegenerative conditions.
Strategy
The company’s strategy is to advance GT-02287 and other Magellan™-derived programs through preclinical and clinical development while preserving liquidity. It also seeks collaboration, licensing, and strategic alliance opportunities to fund development and potentially reduce the capital burden of building a full commercial organization. Because it remains pre-revenue, financing discipline and partnering are central to execution.
Clinical progress is the main source of value creation and partnering leverage.
The company has no product revenue and needs capital to fund development.
A wider target set can increase the probability of partnering and future pipeline value.
Geography
Gain Therapeutics is headquartered in the United States and operates as a U.S.-listed development-stage biotech. Its supply chain is international: the company states that materials for product candidates are currently manufactured in China, creating exposure to trade policy and cross-border sourcing risk. Commercial geography is still limited because it has no approved products or product sales.
Risks
Gain Therapeutics faces the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the need for repeated financing before any product revenue is possible. It also has meaningful supply-chain and geopolitical exposure because key materials are currently manufactured in China, while tariffs or trade restrictions could raise costs and slow development. As a pre-commercial company, its valuation is highly sensitive to trial outcomes, partnering success, and access to capital.
- Financing shortfallImpact: CriticalLikelihood: Low
The company expects continued losses and negative operating cash flow.
Exposure - Clinical development failureImpact: Critical
Lead programs may not demonstrate sufficient safety or efficacy to advance.
Exposure: GT-02287 and future pipeline candidates
- Regulatory delay or non-approvalImpact: HighLikelihood: High
FDA, EMA, or other agencies can slow or block development and commercialization.
Exposure: Clinical-stage product candidates
- China sourcing and tariff exposureImpact: HighLikelihood: Medium
APIs and other materials are currently manufactured in China, increasing cost and supply risk.
Exposure: Clinical supply chain and future manufacturing
Accounting
Judgemental itemsClinical and discovery costs are estimated before invoices are fully settled.
Impact: Can shift quarterly operating loss and liabilities
A meaningful non-cash cost for a small public biotech with limited revenue.
Impact: Affects operating expenses and comparability across periods
Grant income, when present, requires judgment on eligibility and timing.
Impact: Can reduce net loss or offset R&D expense
Future partner deals may require allocation of consideration and timing judgments.
Impact: Could materially affect revenue timing if deals are signed
Similar listed companies
Publicly listed companies with a comparable business focus.
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
Serina Therapeutics, Inc.
SER · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Last updated: 24/09/2026